Literature DB >> 10502516

Mutations in conserved domain II of the large (L) subunit of the Sendai virus RNA polymerase abolish RNA synthesis.

S Smallwood1, C D Easson, J A Feller, S M Horikami, S A Moyer.   

Abstract

The large (L) protein of Sendai virus complexes with the phosphoprotein (P) to form the active RNA-dependent RNA polymerase. The L protein is believed to be responsible for all of the catalytic activities of the polymerase associated with transcription and replication. Sequence alignment of the L proteins of negative-strand RNA viruses has revealed six conserved domains (I-VI) thought to be responsible for the enzymatic activities. Charged-to-alanine mutagenesis was carried out in a highly charged, conserved region (amino acids 533-569) within domain II to test the hypothesis of Müller et al. [J. Gen. Virol. 75, 1345-1352 (1994)] that this region may contribute to the template binding domain of the viral RNA polymerase. The mutant proteins were tested for expression and stability, the ability to synthesize viral RNA in vitro and in vivo, and protein-protein interactions. Five of the seven mutants were completely defective in all viral RNA synthesis, whereas two mutants showed significant levels of both mRNA and leader RNA synthesis. One of the transcriptionally active mutants also gave genome replication in vitro although not in vivo. The other mutant was defective in all the replication assays and thus the mutation uncoupled transcription and replication. Because the completely inactive L mutants can bind to the P protein to form the polymerase complex and the polymerases bind to the viral nucleocapsid template, these amino acids are essential for the activity of the L protein. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10502516     DOI: 10.1006/viro.1999.9933

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  17 in total

1.  Architecture and regulation of negative-strand viral enzymatic machinery.

Authors:  Philip J Kranzusch; Sean P J Whelan
Journal:  RNA Biol       Date:  2012-07-01       Impact factor: 4.652

2.  Genetic and biochemical evidence for an oligomeric structure of the functional L polymerase of the prototypic arenavirus lymphocytic choriomeningitis virus.

Authors:  Ana B Sánchez; Juan C de la Torre
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

3.  Molecular architecture of the vesicular stomatitis virus RNA polymerase.

Authors:  Amal A Rahmeh; Andreas D Schenk; Eric I Danek; Philip J Kranzusch; Bo Liang; Thomas Walz; Sean P J Whelan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

Review 4.  Polymerases of paramyxoviruses and pneumoviruses.

Authors:  Rachel Fearns; Richard K Plemper
Journal:  Virus Res       Date:  2017-01-16       Impact factor: 3.303

5.  Structure and Function of the N-Terminal Domain of the Vesicular Stomatitis Virus RNA Polymerase.

Authors:  Shihong Qiu; Minako Ogino; Ming Luo; Tomoaki Ogino; Todd J Green
Journal:  J Virol       Date:  2015-10-28       Impact factor: 5.103

6.  Role of a highly conserved NH(2)-terminal domain of the human parainfluenza virus type 3 RNA polymerase.

Authors:  Achut G Malur; Suresh K Choudhary; Bishnu P De; Amiya K Banerjee
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

7.  A conserved motif in region v of the large polymerase proteins of nonsegmented negative-sense RNA viruses that is essential for mRNA capping.

Authors:  Jianrong Li; Amal Rahmeh; Marco Morelli; Sean P J Whelan
Journal:  J Virol       Date:  2007-11-14       Impact factor: 5.103

8.  A temperature sensitive VSV identifies L protein residues that affect transcription but not replication.

Authors:  Summer E Galloway; Gail W Wertz
Journal:  Virology       Date:  2009-04-22       Impact factor: 3.616

9.  Analysis of a structural homology model of the 2'-O-ribose methyltransferase domain within the vesicular stomatitis virus L protein.

Authors:  Summer E Galloway; Paul E Richardson; Gail W Wertz
Journal:  Virology       Date:  2008-10-11       Impact factor: 3.616

10.  Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates.

Authors:  Sheila M Nolan; Mario H Skiadopoulos; Konrad Bradley; Olivia S Kim; Stacia Bier; Emerito Amaro-Carambot; Sonja R Surman; Stephanie Davis; Marisa St Claire; Randy Elkins; Peter L Collins; Brian R Murphy; Anne Schaap-Nutt
Journal:  Vaccine       Date:  2007-07-03       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.